Seattle Genetics is a biotechnology and pharmaceutical company based in Bothell, Washington, USA. Mr. Clay B. Siegall is the current President and Chief Executive Officer of the company. It was founded in 1998 and in 2001, completed its initial public offering, and traded as SGEN in Nasdaq Stock market. It currently has a manpower of over 800 people who provide services and help to cancer patients.
The company is dedicated to developing and commercializing therapies based on antibodies, for the treatment of cancer patients. The company is one of the leaders in ADCs (Antibody-drug conjugates); a technology designed to harness the ability of monoclonal antibodies to target and deliver cell-killing agents directly to cancer cells. The ADCs spare the cells that have not been targeted, hence reducing the toxic effects that the traditional chemotherapy treatment method come with, and also enhances antitumor activities.
They also deal in products that address the various medical needs not met.
This is a new program in the new ADCs’ class. The program is run in collaboration with the Takeda Pharmaceutical Company Limited and is approved in more than 60 countries in the world. In a bid to expand ADRCTRIS opportunity, the company is conducting a program in clinical development to evaluate the potential of the ADCRETIS program being the foundation of CD30-expressing lymphomas treatment, including cutaneous T-cell lymphoma, B-cell lymphomas, Hodgkin Lymphoma and mature T-cell lymphoma.
ADCs: Integral Part of Cancer Therapy
33A and ADCETRIS are 2 of the over 20 ADCs in the field of clinical development that use proprietary technology. The company’s ADC technology is employed by collaborators in advancing several programs for antibodies’ empowerment. The company through these collaborations and innovations aim at improving the outcome of patients’ treatments.
SGN-CD33A: Pivotal Phase 3 Program
The company is also advancing Vadastuximab, an ADC novel being evaluated for Acute Myeloid Leukemia. There are many patients suffering from AML, yet in over 30 years of research, there has not been any meaningful advancement made.
About Clay Siegall
Dr. Clay B. Siegall is the co-founder of Seattle Genetics, where he has been the CEO since 2002. He previously has worked with Pharmaceutical Research Institute in the period between 1991 and 1997, and the National Institute of Health years back in 1988 through 1991. He also has a background at Alder Biopharmaceuticals and Fred Hutchincon Cancer Research Business Alliance. His knowledge was obtained from the University of Maryland where he got his bachelor’s degree in Zoology, and George Washington University where he got his Ph.D. in Genetics.